key: cord-0851941-z3urr2f9
authors: Dadon, Ziv; Levi, Nir; Orlev, Amir; Belman, Daniel; Alpert, Evan Avraham; Glikson, Michael; Gottlieb, Shmuel; Butnaru, Adi
title: The Utility of Hand-held Cardiac and Lung Ultrasound in Predicting Outcomes of Hospitalized Patients with COVID-19
date: 2021-12-03
journal: Can J Cardiol
DOI: 10.1016/j.cjca.2021.11.016
sha: 237fb33e1efe700a20498dc12bc21017ebd5d398
doc_id: 851941
cord_uid: z3urr2f9

BACKGROUND: Strict isolation precautions limit formal echocardiogram use in the setting of COVID-19 infection. Information on the importance of the utilization of a hand-held focused ultrasound for cardiac evaluation in these patients is scarce. This study investigated the utility of a hand-held echocardiogram device in COVID-19 hospitalized patients in diagnosing cardiac pathologies and predicting the composite endpoint of in-hospital death, mechanical ventilation, shock, and acute decompensated heart failure. METHODS: From April 28(th) through July 27(th), 2020, consecutive patients diagnosed with COVID-19 underwent evaluation using a hand-held ultrasound (Vscan Extend™ with Dual Probe; GE Healthcare) within 48-h of admission. The patients were divided into two groups: 'Normal' and 'Abnormal' (as defined by biventricular systolic dysfunction/enlargement, or moderate/severe valvular regurgitation/stenosis) echocardiogram study. RESULTS: Among 102 patients, 26 (25.5%) had an abnormal study. They were older, with more co-morbidities, and more severe presenting symptoms, as compared to the group with a normal echocardiogram. The prevalence of the composite outcome among low- and high-risk patients (oxygen saturation <94%) was 3.1% and 27.1%, respectively. Multivariate logistic regression analysis revealed that an abnormal echocardiogram at presentation was independently associated with the composite endpoint (OR 6.19; 95% CI 1.50-25.57, p=0.012). CONCLUSIONS: An abnormal echocardiogram in COVID-19 infection settings is associated with a higher burden of medical comorbidities and independently predict major adverse endpoints. Hand-held focused echocardiogram can be utilized as an important “rule-out” tool among high-risk COVID-19 patients and should be integrated into their routine admission evaluation. However, its routine utilization among low-risk patients is not recommended.

COVID-19 interacts with the cardiovascular system on multiple levels. It is well established that known cardiovascular disease or risk factors are associated with a significant increase in morbidity and mortality among COVID-19 patients. In addition, it has been demonstrated that elevation in cardiac biomarkers such as high-sensitivity cardiac troponin-I (hs-cTnI) is correlated with a poor prognosis in COVID-19

patients. [1] The association between COVID-19 and the cardiovascular system has led researchers to try to better identify predictors for severe disease and adverse outcomes. Possible predictors for disease severity might be cardiac systolic function, including left and right ventricular (RV) systolic function or valvular functional abnormalities as determined by echocardiogram. Routine echocardiographic evaluation of all patients admitted with COVID 19, however, is currently discouraged according to various guidelines and consensus papers due to concerns of excessive workload in the setting of a pandemic, [2, 3] risk of infection of echocardiogram professionals, and equipment contamination which increases with long imaging time. [4] Hand-held ultrasound has been shown to be accurate when used by cardiologists for many aspects of cardiac evaluation. This includes evaluation of left ventricular ejection fraction (LVEF), regional wall motion abnormalities, left ventricular (LV) hypertrophy, not need a sonography technician, can be easily cleaned and can be stored in COVID- 19 units for ease of use without disruption to the clinical setting. Furthermore, some devices can be utilized for lung assessment as well with a quick and > 90% accurate interpretation for common causes of acute respiratory failure. [11] The objective of this study is to characterize the utility of hand-held echocardiogram in COVID-19 hospitalized patients to predict endpoints based on identified cardiac abnormalities including ventricular size and systolic function, and valvular pathologies.

This is a prospective study of real-time focused echocardiogram and lung ultrasound performed using a hand-held device. The study was conducted on consecutive PCRconfirmed COVID-19 patients hospitalized in designated medical wards at a tertiary care medical center from April 28 th through July 27 th , 2020. The study was approved by the hospital's Institutional Review Board.

All echocardiographic clips were acquired by cardiologists or intensivists and were later interpreted by a fellowship-trained echocardiographer. Variables including demographics, past medical history, electrocardiogram (ECG), imaging modalities, and laboratory results were obtained from the medical record.

The primary endpoint was defined as a composite endpoint of in-hospital death, mechanical ventilation, shock and acute decompensated heart failure (ADHF).

Secondary endpoints included the composite endpoint, individual parameters of the composite endpoint, advanced ventilatory support (high-flow nasal cannula, noninvasive positive airway pressure support and invasive ventilation), chronic ventilation, J o u r n a l P r e -p r o o f myocardial injury (defined as >3 times hs-cTnI upper normal limit), venous thromboembolism, anti-COVID-19 drug use, sepsis and length of hospital stay.

Confirmed COVID-19 patients who were hospitalized in designated internal medicine departments were recruited into the study. Conscious patients consented verbally.

Patients who were not able to give informed consent underwent echocardiogram if it was clinically indicated. Patients that refused to participate in the study were excluded.

Basic characteristics included age, sex and known previous medical illness. A routine chest X-ray, ECG, and blood workup were performed for every patient upon admission to the designated COVID-19 wards. The routine laboratory tests included complete blood count, renal function, electrolytes, hs-cTnI, D-dimer, coagulation function tests and C-reactive protein (CRP). Brain natriuretic peptide (BNP) was measured based on the clinical judgment of the treating physician. The study physicians performing the ultrasound examination wore personal protective equipment including a full gown, N95 face mask, face shield, and at least two sets of gloves. Participants were evaluated by 

All data obtained in this study were entered into two Microsoft Excel spreadsheets. One file contained the case identifying number, patient identifiers and other pertinent variables. POCUS results were inserted into a second file using the patient's identifying number. The two files were then matched.

Study participants were divided into normal or abnormal echocardiograms according to POCUS results. Abnormal echocardiograms included those with LVEF <50%, LV dilation, RV systolic dysfunction/dilation, or moderate/severe valvular dysfunction (functional regurgitation or stenosis).

The patients were divided into normal and abnormal echocardiograms, and analyses were performed accordingly. Descriptive statistics were used to analyze differences in baseline and clinical characteristics, echocardiogram and lung ultrasound results and endpoints, using Chi-square or Fisher's exact tests for categorical variables, and the ttest or Mann-Whitney U test for continuous variables, where appropriate. Test selection was based on data distribution and normalcy.

High-risk patients were defined as those with room-air saturation of < 94%. The ability of the echocardiogram results to identify patients with and without the composite outcome was then tested for sensitivity, specificity, positive predictive value and negative predictive value among low and high-risk patients.

Odds ratio (OR) and 95% confidence interval (CI) were calculated to test the univariate associations between abnormal echocardiogram and composite endpoint and individual endpoints.

Multivariate logistic regression analysis (OR and 95% CI) was calculated for the association between abnormal echocardiogram and the composite endpoint among the entire cohort and individually among high-risk patients, including pertinent baseline characteristics covariates (those with p values of less than 0.05). Statistical analyses were performed using SPSS Statistics for Windows version 21 (SPSS Inc., Chicago, IL).

A total of 102 COVID-19 hospitalized patients were recruited into the study, including 76 (74.5%) with a normal and 26 (25.5%) with an abnormal echocardiogram (Table 1) .

Four patients refused to participate in the trial and thus were excluded.

J o u r n a l P r e -p r o o f As shown in Table 1 , the mean age of the total cohort was 59.7±18.4 years, 63.7% were males. Patients with an abnormal echocardiogram were older and more likely to suffer from comorbidities including smoking, hypertension, hyperlipidemia, ischemic heart disease, past revascularization, and heart failure (HF), as compared to patients with a normal echocardiogram. They had a higher proportion of past valve replacement and cardiac implantable electronic devices. Moreover, they were treated more often with chronic HF evidence-based medications, anti-platelets, diuretics, and statins.

As shown in Table 1 , the two groups did not differ in terms of their presenting complaints nor vital signs. Patients with an abnormal echocardiogram had a higher rate of pathological electrocardiograms (including non-specific and ST-segment changes or T-wave inversion) and chest x-ray infiltrates, as compared to those with a normal echocardiogram. Laboratory results of creatinine, hs-cTnI, fibrinogen, activated-partial thromboplastin time, white blood cell count, neutrophil/lymphocyte count ratio, CRP and D-dimer were higher in the abnormal as compared to the normal echocardiogram group while albumin was lower.

Echocardiogram and lung ultrasound results are presented in Table 2 . As compared to patients with a normal echocardiogram, those with an abnormal study had a lower LVEF (49.2±8.2% vs. 57.2±4.1%, p<0.001), higher LVEDD (4.8±0.6 vs. 4.5±0.5, p=0.016), and a higher proportion of LVEF<50%, RV systolic dysfunction and dilation, pericardial effusion, and significant valvulopathy (including significant mitral and tricuspid regurgitation, and aortic stenosis). Comparing lung scores between patients with a normal echocardiogram, to those with abnormal echocardiograms yielded no association (2.9±2.4 vs. 3.7±2.5, p=0.119).

Four patients underwent an official echocardiogram following the study exam during the index hospitalization, which confirmed the findings of the focused echocardiogram.

Echocardiogram results and measurements among patients with and without advanced ventilatory support are also presented in Table 2 

Among the 102 patients included in the study, only 32 are defined as low-risk patients (with room air oxygen saturation ≥ 94%) including 6 patients with an abnormal echocardiogram from which only 1 patient had the composite outcome. The sensitivity of focused echocardiogram for the composite outcome among low-risk patients is 100% and the specificity is 83.9% with a PPV of 16.7% and NPV of 100%.

Among the 70 patients defined as high-risk (with room air oxygen saturation < 94%), the sensitivity of focused exam for the composite outcome is 57.9% and the specificity is 82.4% with a PPV of 55.0% and NPV of 84.0%.

The associations between an abnormal echocardiogram and the endpoints are presented in Table 3 and Figure 1 . An abnormal echocardiogram was associated with the endpoints of the need for advanced ventilatory support, ADHF, myocardial injury, acute kidney injury, death, and with the composite endpoint (in-hospital death, mechanical ventilation, shock, and ADHF; unadjusted OR 7.29, 95% CI 2.44-20.00).

Multivariate analysis adjusting for age, heart failure, ischemic heart disease, smoking, hypertension, hyperlipidemia, prior revascularization, cardiovascular implantable electronic device (CIED) implantation or valve replacement revealed that among the entire cohort an abnormal echocardiogram was independently associated with a higher probability for the composite endpoint (OR 6.19; 95% CI 1.50-25.57, p= 0.012).

Multivariate analysis adjusting for age, heart failure, hypertension, hyperlipidemia, smoking and CIED implantation revealed that among high-risk patients an abnormal echocardiogram was independently associated with a higher probability for the composite endpoint (OR 5.47; 95% CI 1.29-23.30, p= 0.022).

The lung score was associated with the endpoints of the need for advanced ventilatory support, anti-COVID medication use, myocardial injury, hospital length of stay, mechanical ventilation, ADHF, in-hospital death, and with the composite endpoint (unadjusted OR 1.44, 95% CI 1.18-1.77).

Multivariate analysis adjusting for the above pertinent variables revealed that the continuous lung score was independently associated with a higher probability for the composite endpoint (OR 1.56; 95% CI 1.12-2.03, p= 0.001).

The current study is, to the best of our knowledge, the first to investigate the utility of healthcare systems necessitates achieving an appropriate balance between the relative necessity of the exam and the duty of sonographers, nurses, advanced practice providers, and physicians to provide high-quality imaging while limiting viral spread, reducing staff exposure and protecting patients. In these settings, traditional criteria for echocardiogram use seem too extensive and clinicians are required to prioritize the need for this valuable resource. The handheld devices have smaller non-sterile exposed areas compared to standard machines, can be easily decontaminated with disinfectant wipes and their size allows for them to be entirely enclosed by a sterile covering thereby limiting iatrogenic virus transmission. [12, 13] The findings of the current study support the acquisition of a cardiac assessment sonographic tool that can be dedicated to the COVID-19 departments and can be operated more conveniently in accordance with recommended precautions.

An abnormal echocardiogram was observed in 25.5% of the study population. Other studies using standard cart-based machines or laptops and conducted on COVID-19 J o u r n a l P r e -p r o o f hospitalized patients have found a relatively high rate of sonography-based cardiac abnormalities ranging up to 68% with RV systolic dysfunction being the most predominant finding (10-52.8%). [14] [15] [16] [17] [18] [19] [20] This discrepancy may be explained by selection bias (patients with advanced illness), differing timelines between echocardiogram performance and disease onset, lack of Doppler usage, partial RV visualization, and discrepancies in the definition of an abnormal echocardiogram.

Another important difference is the use of high-end devices or detailed full echocardiogram examinations in most of the studies. As none of the studies used handheld ultrasound, their examination may be more meticulous but less practical in the COVID-19 clinical setting.

An example of studies focusing on patients with advanced illness is one in which an echocardiogram was only performed after approval by three physicians and on patients with an elevated high sensitivity troponin or a clinical need for the exam. [19] In this study, 82% of the patients required mechanical ventilation and 58% required vasopressor support. A correlation between disease severity and the prevalence of an abnormal echocardiogram can be found in a cross-sectional study comparing patients with non-severe COVID-19 to those with severe disease, demonstrating larger biventricular diameters alongside lower LVEF and RV FAC in those with severe disease. [21] An association between mortality and cardiac abnormality on echocardiogram was also found in Karagodin et al., demonstrating an association between both LV and RV strain and mortality. [22] However, the routine utilization of strain for ventricular assessment is limited for patients hospitalized in COVID-19 designated departments. Also, unlike in our study, their cohort included a very high in-hospital mortality rate of 21.6% that may reflect selection bias of patients with more severe COVID-19.

Limitations This is a prospective, single-center, observational study and not a randomized trial, and as such is subjected to associated confounding factors. However, after constructing a multivariate analysis, the independent predictive value remained substantial. Also, data regarding prior echocardiogram studies are lacking and not included in the analysis.

Lack of pulsed and continuous-wave Doppler usage and simultaneous electrocardiogram limit the evaluation of valvular pathologies, hemodynamics, and echocardiographic images which may have led to an underestimation of cardiac pathologies. Nonetheless, the study provides data in real-world settings that are relevant to the day-to-day limited clinical use of POCUS echocardiogram in COVID-19 wards.

A prospective POCUS study with non-cardiologists vs. cardiologists and low-risk vs.

high-risk patients would assist in clarifying the limitations of the current study. 

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

ASE Statement on Protection of Patients and Echocardiography Service Providers During the 2019 Novel Coronavirus Outbreak: Endorsed by the American College of Cardiology

COVID-19 pandemic and cardiac imaging: EACVI recommendations on precautions, indications, prioritization, and protection for patients and healthcare personnel

Point-of-care screening for left ventricular hypertrophy and concentric geometry using hand-held cardiac ultrasound in hypertensive patients

Point of care ultrasound: a WFUMB position paper

E-point septal separation: a bedside tool for emergency physician assessment of left ventricular ejection fraction

Echocardiography in the emergency department

Lung Ultrasound for Cardiologists in the Time of COVID-19

Prime time for handheld echocardiography in COVID-19 pandemic

Handheld ultrasound devices: An emerging technology to reduce viral spread during the Covid-19 pandemic

Spectrum of cardiac manifestations in COVID-19: a systematic echocardiographic study

The prevalence, risk factors and outcome of cardiac dysfunction in hospitalized patients with COVID-19

Indications for and findings on transthoracic echocardiography in COVID-19

Impact of right ventricular dysfunction on mortality in patients hospitalized with COVID-19, according to race

Cardiac function in relation to myocardial injury in hospitalised patients with COVID-19

Echocardiographic findings in patients with COVID-19 pneumonia

Global evaluation of echocardiography in patients with COVID-19

Echocardiographic features of patients with COVID-19 infection: a cross-sectional study

Echocardiographic Correlates of In-Hospital Death in Patients with Acute COVID-19 Infection: The World Alliance Societies of Echocardiography (WASE-COVID) Study

Acknowledgment: The authors thank GE Healthcare for the temporary supply of a Vscan Extend™ ultrasound device for research purposes.

Chest X-ray infiltrates, n (%) 75 aPTT (p), mean ± SD 35.0 ± 9.7 33.9 ± 9.7 38.1 ± 9.2 0.009